Le Lézard
Classified in: Health, Science and technology, Business
Subject: JVN

MIM Software Inc. to Collaborate with Sirtex Medical to Provide Patient-Specific Y-90 Dosimetry


CLEVELAND, Feb. 12, 2020 /PRNewswire/ -- MIM Software Inc., a leading global provider of medical imaging software, announced today a collaboration with Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, that will provide patient-specific dosimetry of Yttrium-90 (Y-90) microspheres globally.

(PRNewsfoto/MIM Software Inc.)

As part of this collaboration, Sirtex will now have the ability to provide MIM Software's MIM SurePlantm LiverY90 software solution alongside the company's SIR-Spheres® Y-90 resin microspheres. This will help quantify and improve Y-90 treatments that benefit patients in the overall treatment care path. MIM Software will continue to provide its industry-leading service and support directly to Sirtex customers.  

MIM SurePlan LiverY90 provides timesaving tools for liver and tumor segmentation and allows for patient-specific dose calculation on Y-90 PET and Bremsstrahlung SPECT images after administration of permanent Y-90 microsphere implants. Patient-specific dosimetry provides immediate quantitative data, allowing physicians to make quick and informed decisions about next steps for treatment.

"This collaboration represents a tremendous opportunity to make tools like patient-specific dosimetry available to a much larger number of sites," said Andrew Nelson, Chief Executive Officer of MIM Software, Inc. "We believe that patient-specific dosimetry will enable clinicians to make more informed treatment decisions and thus have a positive impact on patient care. Additionally, Sirtex's close connection to and understanding of its customers will help us provide a solution that will be very relevant to customer needs."

"We are excited to partner with MIM Software and for our teams to work together to deliver innovative solutions to our customers," said Kevin Smith, Chief Executive Officer of Sirtex. "Combining our expertise and resources in treating hepatic tumors will provide an even higher level of support to clinicians and ultimately improve treatment outcomes for patients."

Y-90 microspheres deliver local radiation as permanent brachytherapy implants to tumors in the liver. Currently, PET or SPECT images are obtained after treatment to verify the distribution of microspheres. Now, absorbed dose from the Y-90 microspheres can be calculated on a voxel-by-voxel basis using the PET or SPECT images.

About MIM Software Inc.
MIM Software Inc. is committed to enhancing patient care by providing customer-centered and innovative imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, neuroimaging, and cardiac imaging. Headquartered in Cleveland, OH, MIM Software is a privately held company with offices worldwide. For more information, visit www.mimsoftware.com.

About Sirtex Medical
Sirtex Medical is a global healthcare business with offices in the U.S., Australia, Germany and Singapore, working to improve outcomes in people with cancer. Its current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,300 medical centers in over 50 countries. For more information, visit www.sirtex.com.

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

SOURCE MIM Software Inc.


These press releases may also interest you

at 08:26
On 4 June 2020 a total of 4,431 own shares (CAV1V) have been returned to Caverion Corporation. The receipt of shares is related to the directed share issue announced on 18 December 2019, whereby shares held by the company were conveyed as payment...

at 08:25
The "Artificial Intelligence Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. This report provides the strategists, marketers and senior management with the critical information...

at 08:20
Technavio has been monitoring the regenerative medicine market and it is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the forecast period. The report offers an up-to-date analysis regarding the current...

at 08:20
Ballogy Inc., the innovative software company revolutionizing the way youth and amateur athletes prepare for their sports, today announced it is partnering with PGC Basketball (PGC), the largest educational basketball program in the world, to launch...

at 08:17
While the world watches the coronavirus (COVID-19) pandemic wash over its communities, medical workers are enduring seemingly endless days caring for the sick. Two young brothers have decided to put their skills to good use, dedicating months of...

at 08:16
New research from Parks Associates, fielded nationwide between March 8th and April 3rd, finds 15% of US broadband households report their usage of telehealth/remote doctor services has increased as a result of the COVID-19 pandemic. The research firm...



News published on 12 february 2020 at 09:00 and distributed by: